Veena Rao, PhD
Research ScientistCards
About
Research
Publications
2025
Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure
Hubbell K, Rao V, Scherzer R, Shlipak M, Ivery‐Miranda J, Bansal N, Cox Z, Testani J, Estrella M. Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure. ESC Heart Failure 2025, 12: 3296-3305. PMID: 40504107, PMCID: PMC12450773, DOI: 10.1002/ehf2.15342.Peer-Reviewed Original ResearchAcute decompensated heart failureDecompensated heart failureDiuretic responseHeart failureHF rehospitalizationRisk of HF rehospitalizationBiomarker modelAssociated with poor outcomesAssociated with decreased riskAssociated with increased riskAssociated with cardiometabolic diseasesAssociated with mortalityAssociated with rehospitalizationDiuretic resistanceMedian ageResistance cohortClinical factorsPoor outcomeSociodemographic/lifestyle factorsPrognostic toolCombined biomarkersCardiometabolic diseasesPatientsAmbulatory settingMortality riskEvaluation of the Natriuretic Response Prediction Equation Using a Race-free Estimated Glomerular Filtration Rate Equation
Cox Z, Rao V, Wrenn J, Collins S, Testani J, Ivey-Miranda J. Evaluation of the Natriuretic Response Prediction Equation Using a Race-free Estimated Glomerular Filtration Rate Equation. Journal Of Cardiac Failure 2025, 31: 1582-1586. PMID: 40441408, DOI: 10.1016/j.cardfail.2025.05.013.Peer-Reviewed Original ResearchNatriuretic response prediction equation for use with oral diuretics in heart failure
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mastache D, Collins S, Testani J. Natriuretic response prediction equation for use with oral diuretics in heart failure. European Heart Journal 2025, 46: 2410-2418. PMID: 40272149, PMCID: PMC12208776, DOI: 10.1093/eurheartj/ehaf268.Peer-Reviewed Original ResearchConceptsMechanisms of diuretic resistanceArea under the curvePoor diuretic responseDiuretic responseHeart failureDiuretic doseOral diureticsNatriuretic responseHF patient cohortsLoop diuretic doseOral loop diureticsUrine samplesTimed urine collectionsOral loopDiuretic resistanceLoop diureticsDiuretic administrationUrine volumePatient cohortUrine collectionStudy visitsDiureticsPatientsUrineDoseReprieve System for the Treatment of Patients With Acute Decompensated Heart Failure
Ivey-Miranda J, Rao V, Shaburishvili T, Verulava I, Khabeishvili N, Petrie M, Butler J, Nunez J, Biegus J, Ponikowski P, Damman K, Collins S, Testani J, Cox Z. Reprieve System for the Treatment of Patients With Acute Decompensated Heart Failure. Journal Of Cardiac Failure 2025, 31: 1085-1089. PMID: 39947422, DOI: 10.1016/j.cardfail.2025.02.002.Peer-Reviewed Original Research
2024
Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal
Asher J, Ivey-Miranda J, Maulion C, Cox Z, Borges-Vela J, Mendoza-Zavala G, Cigarroa-Lopez J, Silva-Rueda R, Revilla-Monsalve C, Moreno-Villagomez J, Ramos-Mastache D, Goedje O, Crosbie I, McIntyre C, Finkelstein F, Turner J, Testani J, Rao V. Development of a Novel Intraperitoneal Icodextrin/Dextrose Solution for Enhanced Sodium Removal. Kidney Medicine 2024, 7: 100938. PMID: 39790231, PMCID: PMC11714391, DOI: 10.1016/j.xkme.2024.100938.Peer-Reviewed Original ResearchPD solutionsPeritoneal dialysisSodium removalIcodextrin PD solutionExposure of miceLong-term safetyClearance of uremic toxinsChronic therapyEdematous disordersStructural tissue changesAdverse eventsRemoval therapyEfficacy resultsHeart failureEvaluate safetyNet ultrafiltrationUremic toxin clearanceAnimal modelsIcodextrinKidney failureUremic toxinsTissue changesAscending concentrationsEfficient ultrafiltrationEfficacyMechanistic Differences between Torsemide and Furosemide
Rao V, Cox Z, Ivey-Miranda J, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang W, Collins S, Velazquez E, Mentz R, Wilson F, Turner J, Wilcox C, Ellison D, Fang J, Testani J. Mechanistic Differences between Torsemide and Furosemide. Journal Of The American Society Of Nephrology 2024, 36: 99-107. PMID: 39196651, PMCID: PMC11706557, DOI: 10.1681/asn.0000000000000481.Peer-Reviewed Original ResearchTorsemide groupDiuretic doseTubular site of actionHigher diuretic dosesDose of furosemideProportion of dosesOral furosemideSite of actionPrescribed doseNeurohormonal activationMechanistic substudyClinical outcomesPharmacodynamic advantagesKidney dysfunctionPharmacodynamic parametersKidney functionRandomized trialsNatriuresisTubular sitesFurosemideTorsemideDoseTRANSFORM-HFPlasma volumeBody weightThe utility of urine sodium–guided diuresis during acute decompensated heart failure
Siddiqi H, Cox Z, Stevenson L, Damman K, ter Maaten J, Bales B, Han J, Ivey-Miranda J, Lindenfeld J, Miller K, Ooi H, Rao V, Schlendorf K, Storrow A, Walsh R, Wrenn J, Testani J, Collins S. The utility of urine sodium–guided diuresis during acute decompensated heart failure. Heart Failure Reviews 2024, 29: 1161-1173. PMID: 39128947, PMCID: PMC11455821, DOI: 10.1007/s10741-024-10424-8.Peer-Reviewed Original ResearchAcute decompensated heart failureDecompensated heart failureHeart failureClinical trialsUrine sodium excretionObservational cohort studyRandomized clinical trialsAdequate decongestionDiuretic strategySodium excretionUrine chemistryCohort studyTitration strategyUrineDiuretic titrationAdverse effectsDiuresisDecongestionPatientsUsual careEvidence gapsTrialsTherapyFailureIncreased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion
Natov P, Ivey-Miranda J, Cox Z, Rao V, Butler J, Konstam M, Kiernan M, Kapur N, Testani J. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. Journal Of Cardiac Failure 2024, 30: 1522-1526. PMID: 38986838, DOI: 10.1016/j.cardfail.2024.06.008.Peer-Reviewed Original ResearchBaseline serum potassiumAcute heart failureSerum potassiumSpironolactone treatmentTreatment armsHeart failureBaseline serum potassium levelsNatriuretic peptide levelsTreated with spironolactoneSerum potassium levelsSpironolactone-treated patientsNet fluid lossRenal potassium handlingPost Hoc AnalysisEnhance decongestionSpironolactone dosePotassium wastingUrine outputClinical congestionTreatment startPotassium handlingPotassium replacementPotassium supplementationPharmacodynamic effectsSurrogate markerInterleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individualsSerial direct sodium removal in patients with heart failure and diuretic resistance
Rao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.Peer-Reviewed Original ResearchConceptsDiuretic resistanceCardiorenal syndromeHeart failureLoop diureticsDiuretic withdrawalHigh-dose loop diureticsN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideGrowth differentiation factor 15Carbohydrate antigen 125Differentiation factor 15Sodium removalRandomized Controlled StudyCardiorenal parametersDiuretic doseSoluble ST2Natriuretic peptideMedian timeDiuretic responseKidney injuryPeritoneal membraneElectrolyte handlingKidney functionDiureticsInterleukin-6
Clinical Trials
Current Trials
Mechanisms of Diuretic Resistance in Heart Failure (MsDR)
HIC ID2000032328RoleSub InvestigatorPrimary Completion Date03/31/2028Recruiting ParticipantsGenderBothAge18+ years
Academic Achievements & Community Involvement
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
135 College St
New Haven, CT 06510
United States